Study in The Lancet Finds Pregnant Women Used Less Tylenol After Trump's Public Warning

A single public statement from a president can move medical behavior faster than years of peer-reviewed research. That uncomfortable fact sits at the center of a new study published in The Lancet, which found that pregnant women visiting emergency rooms used acetaminophen — the active ingredient in Tylenol — significantly less frequently after President Trump made a public announcement in September 2025 claiming the pain reliever could raise babies' risk of developmental issues. The behavioral shift was measurable and rapid. Whether it was medically appropriate is a much more complicated question — and the study authors are worried about the answer.

Trump's comments drew from a contested body of observational research that has suggested associations between acetaminophen use during pregnancy and neurodevelopmental outcomes including autism and ADHD. That research has been debated vigorously within obstetrics, epidemiology, and pediatrics for years. The associations found in observational studies are difficult to interpret causally — women who experience more pain or fever during pregnancy may use more acetaminophen, and pain and fever themselves affect fetal development in ways that are hard to disentangle from any drug effect. Major medical organizations, including the American College of Obstetricians and Gynecologists, have maintained that acetaminophen remains the safest available pain reliever for pregnant women when used at recommended doses and for appropriate indications.

What the Study Actually Measured

The Lancet study analyzed electronic health records from emergency departments across multiple hospital systems, comparing acetaminophen administration rates in pregnant patients before and after Trump's September 2025 announcement. The methodology controlled for seasonal variation, patient acuity, and other factors that might independently affect analgesic prescribing patterns. The reduction in acetaminophen use in the post-announcement period was statistically significant and represented a genuine shift in clinical practice rather than random variation — though the study design could not definitively determine whether the change was driven by patient refusal, physician hesitancy, or some combination of both.

The concern raised by the researchers is straightforward: acetaminophen is used in emergency settings for a reason. Pregnant women present to emergency departments with fever, pain from injury, dental pain, headaches, and a range of other conditions where analgesic treatment is clinically indicated. Acetaminophen is specifically recommended in pregnancy precisely because the alternatives — NSAIDs like ibuprofen and naproxen — carry their own established pregnancy risks, including effects on fetal kidney development and premature closure of the ductus arteriosus if used in the third trimester. If pregnant women are refusing or being undertreated with acetaminophen, what are they being treated with instead? And is undertreated pain or fever a safer alternative?

The Science Behind the Warning — Genuinely Contested

The research on acetaminophen and neurodevelopmental outcomes in children is real, peer-reviewed, and published in credible journals. It is also methodologically complex in ways that make its clinical implications genuinely uncertain. A 2021 consensus statement signed by dozens of researchers called for caution and recommended that pregnant women use acetaminophen only when necessary and for the shortest effective duration. That statement represented a serious scientific perspective from scientists who had studied the question carefully.

But the epidemiology of observational associations is not straightforward causation. The studies linking acetaminophen to developmental outcomes are almost entirely observational — they compare children of mothers who used acetaminophen with children of mothers who did not, and find differences in developmental outcomes. The fundamental problem is that the reason a woman uses acetaminophen during pregnancy — a fever, significant pain, an underlying condition — may itself affect fetal development. Mothers who use acetaminophen may be sicker, more stressed, or dealing with conditions that independently affect child development. Controlling for these confounders statistically is possible but never complete.

Animal studies have shown that acetaminophen can affect testosterone signaling and other developmental pathways at certain doses, which provides a plausible biological mechanism for the observed associations. But rodent studies involve doses and exposures that do not straightforwardly translate to typical human use, and the mechanistic evidence has not resolved the fundamental uncertainty about what the epidemiological associations mean for clinical practice at normal therapeutic doses. The scientific community remains genuinely divided, and organizations like ACOG have been careful not to recommend avoidance of acetaminophen when it is clinically indicated.

The Problem With Political Figures Communicating Contested Medical Science

There is a difference between a scientific debate and a public health communication, and what Trump's announcement demonstrated is how consequentially those two things can diverge. A scientific debate involves researchers examining evidence, acknowledging uncertainty, and refining consensus through the peer review process. That process, applied to acetaminophen in pregnancy, had produced a nuanced message: use it cautiously, not routinely, at the lowest effective dose for the shortest necessary duration. That message is appropriate for scientific audiences who can reason about probabilistic risk.

A public announcement from the president does not communicate nuance. It communicates a simple directive to millions of people, many of whom will apply it categorically rather than probabilistically. A pregnant woman who hears that the president said Tylenol raises babies' risk of developmental issues does not go home and read the epidemiological literature. She avoids Tylenol. All of it, in all circumstances, regardless of whether her specific situation is one where the benefit of using it clearly outweighs the uncertain risk. The behavioral finding in the Lancet study — a broad reduction in acetaminophen use across emergency settings — is exactly what one would expect from that kind of categorical, undifferentiated behavioral change.

The study authors noted particular concern about what happens when a pregnant woman with a high fever in an emergency department refuses acetaminophen. High maternal fever during the first trimester is associated with increased risk of neural tube defects and other developmental abnormalities — risks that are better established and more clearly causal than the observational associations between acetaminophen and neurodevelopmental outcomes. A physician treating a febrile pregnant patient who refuses the safest available antipyretic because the president said it was dangerous is in a genuinely difficult clinical position, and the patient may be taking on a more concrete risk to avoid a more speculative one.

The Alternate Analgesics Problem

Emergency physicians treating pregnant women who refuse acetaminophen face limited and worse alternatives. NSAIDs are contraindicated in the third trimester and are used cautiously in earlier pregnancy because of their effects on platelet function and fetal development. Opioids are available for severe pain but carry their own significant risks in pregnancy, including neonatal abstinence syndrome, and are not appropriate for mild to moderate pain management. The result is that some patients who would have received appropriate, safe, effective analgesia may instead go undertreated, which has its own consequences for patient wellbeing and potentially for maternal and fetal outcomes.

Non-pharmacological pain management — ice, rest, positioning — is appropriate for some conditions but clearly inadequate for others. A pregnant woman presenting to an emergency department with significant dental pain, a kidney stone, or a significant musculoskeletal injury needs effective analgesia, and the alternatives to acetaminophen in that context are not simply 'no medication.' They are worse medications or inadequate treatment. Whether the shift in prescribing observed in the Lancet study translated into worse clinical outcomes for the patients involved is something that will require further research to determine, but the study provides the baseline evidence that the behavior changed in a clinically significant direction.

A Pattern That Medical Researchers Recognize and Worry About

The phenomenon the Lancet study documents — political communication producing rapid, broad behavioral changes that outpace and sometimes conflict with medical consensus — is not new. COVID-19 produced multiple examples on different sides of the political spectrum: early hydroxychloroquine enthusiasm following presidential promotion, vaccine hesitancy shaped by politically coded messaging, and mask compliance patterns that tracked political affiliation more than local outbreak severity. The lesson researchers took from that period — that political figures can move health behavior with a speed and scale that public health agencies cannot match — is directly relevant to the acetaminophen finding.

The specific danger with pregnancy health is the vulnerability of the patient population. Pregnant women are often anxious about exposures and eager to avoid any risk to their developing baby — a completely understandable orientation. They are also operating in an information environment where authoritative-sounding sources regularly disagree, where social media amplifies both legitimate caution and unfounded fear, and where a presidential statement carries an implicit authority that is difficult to contextualize against a more nuanced clinical recommendation. The Lancet study shows that this vulnerability is real and measurable.

What Pregnant Women Should Actually Know

The current medical consensus, as maintained by ACOG and major obstetric and pediatric organizations in the US and internationally, is that acetaminophen is the safest available over-the-counter analgesic and antipyretic for use during pregnancy when clinically indicated. The recommendation is not to use it casually or routinely — not for every minor discomfort — but to use it when needed for significant pain or fever that warrants treatment, at the lowest effective dose, for the shortest necessary duration. This is a nuanced recommendation that distinguishes between appropriate and excessive use, not a blanket warning.

Pregnant women who have concerns about acetaminophen — whether those concerns arose from the president's comments, social media, or their own research — should discuss them with their obstetrician or midwife rather than making unilateral decisions to avoid the medication entirely. The clinician can help evaluate the specific clinical situation, weigh the realistic risks and benefits, and recommend an approach that accounts for the individual patient's pregnancy stage, health status, and the specific condition being treated. That individualized conversation is the appropriate locus for decision-making about medication in pregnancy — not a presidential press conference.